Cabotegravir Long-Acting (LA) Injectable Nanosuspension
WHO recommends long-acting cabotegravir for HIV prevention
UNAIDS welcomes the approval of long-acting injectable cabotegravir as a pre-exposure prophylaxis for HIV prevention | UNAIDS
Long-acting antiretroviral therapy | Nature Materials
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study - The Lancet
Cabotegravir - Anwendung, Wirkung, Nebenwirkungen | Gelbe Liste
Cabotegravir Long-Acting (LA) Injectable Nanosuspension
Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial - The Lancet HIV
Cabotegravir long-acting for PrEP registrations in Sub-Saharan Africa | EATG
Discussion Paper: Research Priorities for Implementing Long-acting Injectable Cabotegravir for PrEP in Australia
Hydrogel-forming microarray patches with cyclodextrin drug reservoirs for long-acting delivery of poorly soluble cabotegravir sodium for HIV Pre-Exposure Prophylaxis - Pharma Excipients
Tremendously exciting” news of cabotegravir long-acting injectable for PrEP shared at AIDS 2020 - San Francisco AIDS Foundation
Q&A on long-acting cabotegravir (CAB-LA) for pre-exposure prophylaxis (PrEP) - World | ReliefWeb
ICAP Grand Rounds Webinar — Long-Acting Injectable Cabotegravir for HIV Prevention: Promises and Pitfalls - ICAP at Columbia University
Ausgabe 3/2020: Long-Acting-Medikamente: Option für die PrEP
Thigh injections could be an option for long-acting cabotegravir and rilpivirine | aidsmap
NICE approves long-acting cabotegravir and rilpivirine injections in England and Wales | HTB | HIV i-Base
HIV AIDS Treatment - Cabotegravir & Rilpivirine long acting injectable medicine for HIV patients - YouTube
Long-acting injectable treatment maintains HIV viral suppression. - Thailand Medical News
FDA Approves Cabenuva, the First Complete Long-Acting Injectable HIV Treatment - POZ
Cabotegravir (GSK744, GSK1265744) – Absource Diagnostics
ViiV Healthcare announces US FDA approval of Apretude (cabotegravir extended-release injectable suspension), the first and only long-acting injectable option for HIV prevention | Business Wire
Cabenuva (cabotegravir and rilpivirine) for the Treatment of HIV, USA
Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study - The Lancet HIV
New formulations and alternative injection sites might allow self-administration of long-acting cabotegravir and rilpivirine | aidsmap
NICE approves long-acting cabotegravir and rilpivirine injections in England and Wales | EATG
A long-acting injectable pre-exposure prophylaxis for HIV prevention approved - Drug Policy Network SEE
